Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydroartemisinin in Systemic Lupus Erythematosus
NCT03396393Phase 2Unknown
- Start
- Mar 2018
- Primary completion
- Dec 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
A Phase 2 trial of dihydroartemisinin in systemic lupus erythematosus (SLE). Status: unknown.
02
Drugs
dihydroartemisinin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03396393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03396393.